Hidroclorotiazida Kern Pharma (Hydrochlorothiazide)

Hydrochlorothiazide, the active component of Hidroclorotiazida Kern Pharma, is commonly prescribed for several cardiovascular and renal conditions.

• Management of essential hypertension, often as part of combination therapy.
• Reduction of fluid accumulation (edema) associated with chronic heart failure.
• Treatment of peripheral or pulmonary edema linked to renal insufficiency.
• Control of ascites and peripheral edema in patients with liver cirrhosis.
• Adjunctive therapy for hypercalcemia or calcium‑containing kidney stones in selected cases.

• Hydrochlorothiazide acts on the distal convoluted tubule of the nephron by inhibiting the Na⁺/Cl⁻ symporter. This blockade reduces reabsorption of sodium and chloride, leading to increased excretion of these ions together with water. The resulting mild natriuresis and diuresis decrease extracellular fluid volume, lowering cardiac output and peripheral vascular resistance, which contributes to blood pressure reduction. The effect is dose‑dependent and may be enhanced when combined with other antihypertensive agents.

Like other thiazide diuretics, Hidroclorotiazida Kern Pharma can produce a range of adverse reactions, most of which are mild and reversible.

Common

• Increased frequency of urination, especially during the first weeks of therapy.
• Mild electrolyte disturbances such as low potassium (hypokalemia) or low sodium (hyponatremia).
• Slight rise in blood uric acid levels, which may precipitate gout attacks.
• Transient dizziness or light‑headedness related to volume depletion.

Serious

• Severe electrolyte imbalance, including marked hypokalemia or hypercalcemia.
• Acute kidney injury manifested by sudden rise in serum creatinine.
• Allergic reactions ranging from skin rash to angioedema.
• Pronounced hypotension leading to syncope.

Before initiating Hidroclorotiazida Kern Pharma, clinicians should evaluate patient-specific factors and monitor relevant parameters during treatment.

• Assess renal function; avoid use in patients with severe impairment (eGFR <30 mL/min/1.73 m²).
• Monitor serum electrolytes, particularly potassium, sodium, and calcium, at baseline and periodically.
• Use caution in individuals with a history of gout, as uric acid levels may increase.
• Evaluate blood pressure regularly to prevent excessive hypotension.
• Consider pregnancy category B1; discuss potential risks with pregnant women.
• Review concomitant medications that may potentiate diuretic effects or electrolyte loss.

Hydrochlorothiazide can interact with several drugs, altering its efficacy or increasing the risk of adverse events.

Avoid

• Concurrent use with lithium, which may raise lithium concentrations and cause toxicity.
• Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) that can blunt diuretic response and impair renal function.
• Co‑administration with other potent diuretics (e.g., loop diuretics) without dose adjustment.

Use with caution

• ACE inhibitors, ARBs, or beta‑blockers, which may enhance antihypertensive effect and require blood pressure monitoring.
• Antidiabetic agents, as thiazides can increase blood glucose levels.
• Digoxin, because electrolyte shifts (especially hypokalemia) can predispose to digoxin toxicity.